West Pharmaceutical Services (NYSE:WST) Updates FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 6.000-6.200 for the period, compared to the consensus estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

Analysts Set New Price Targets

WST has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 target price on the stock in a research note on Friday. StockNews.com upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Tuesday. KeyCorp lowered their target price on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research note on Friday. Citigroup began coverage on shares of West Pharmaceutical Services in a research note on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price target for the company. Finally, UBS Group raised shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $350.00 to $390.00 in a report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $344.00.

West Pharmaceutical Services Price Performance

NYSE WST opened at $214.84 on Friday. The company has a 50-day moving average price of $327.86 and a 200-day moving average price of $313.82. West Pharmaceutical Services has a 52 week low of $197.01 and a 52 week high of $400.88. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $15.56 billion, a P/E ratio of 31.87, a PEG ratio of 19.31 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. Equities research analysts anticipate that West Pharmaceutical Services will post 6.67 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, February 11th. Investors of record on Friday, February 7th were given a dividend of $0.21 per share. The ex-dividend date of this dividend was Friday, February 7th. This represents a $0.84 annualized dividend and a yield of 0.39%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.46%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.